Q4 2025 · 13F-HR
Vestal Point Capital, LPholdings as filed
Filed 2026-02-17 · accession 0001974915-26-000002
$2.94B
Reported value
76
Positions
2025-12-31
Period end
The Brief · Vestal Point Capital, LP · Q4 2025
AI · grounded in 13F
Vestal Point Capital, LP established a new position in Abivax SA ABVX worth $256.2M. The fund also initiated new stakes in Invesco QQQ Trust Series 1 QQQ for $215M and Arcellx Inc ACLXGBX for $190.7M. Additional new positions include Terns Pharmaceuticals Inc 430 and BioMarin Pharmaceutical Inc BMRN.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 00370M103 | ABVX | Abivax SA | $256.2M | 8.71% | 1,900,000 | Common | SOLE |
| 46090E103 | QQQ | Invesco QQQ Trust Series 1 | $215.0M | 7.31% | 350,000 | PUT | SOLE |
| 03940C100 | ACLXGBX | Arcellx Inc | $190.7M | 6.48% | 2,925,000 | Common | SOLE |
| 880881107 | 430 | Terns Pharmaceuticals Inc | $181.8M | 6.18% | 4,500,000 | Common | SOLE |
| 09061G101 | BMRN | BioMarin Pharmaceutical Inc | $178.3M | 6.06% | 3,000,000 | Common | SOLE |
| 379577208 | GMED | Globus Medical Inc | $111.3M | 3.78% | 1,275,000 | Common | SOLE |
| 67080M103 | NRIX | Nurix Therapeutics Inc | $89.0M | 3.02% | 4,690,000 | Common | SOLE |
| H01301128 | ALC | Alcon AG | $87.1M | 2.96% | 1,105,000 | Common | SOLE |
| 252131107 | DXCM | Dexcom Inc | $84.6M | 2.88% | 1,275,000 | Common | SOLE |
| 58933Y105 | MRK | Merck & Co Inc | $81.6M | 2.77% | 775,000 | Common | SOLE |
| 877619106 | TSHA | Taysha Gene Therapies Inc | $75.6M | 2.57% | 13,750,000 | Common | SOLE |
| 002824100 | ABT | Abbott Laboratories | $75.2M | 2.56% | 600,000 | Common | SOLE |
| N44445109 | IMTX | Immatics NV | $64.3M | 2.19% | 6,125,000 | Common | SOLE |
| 90240B106 | TYRA | Tyra Biosciences Inc | $63.8M | 2.17% | 2,425,000 | Common | SOLE |
| 055477103 | BCAX | Bicara Therapeutics Inc | $60.2M | 2.05% | 3,575,000 | Common | SOLE |
| 04280A100 | ARWR | Arrowhead Pharmaceuticals Inc | $59.8M | 2.03% | 900,000 | Common | SOLE |
| 29337E102 | ELVN | Enliven Therapeutics Inc | $59.0M | 2.01% | 3,830,000 | Common | SOLE |
| 254604101 | IRON | Disc Medicine Inc | $58.4M | 1.98% | 735,000 | Common | SOLE |
| G50871105 | JAZZ | Jazz Pharmaceuticals PLC | $49.3M | 1.68% | 290,000 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals Inc | $48.5M | 1.65% | 5,200,000 | Common | SOLE |
| 52886X107 | LXEO | Lexeo Therapeutics Inc | $44.4M | 1.51% | 4,475,000 | Common | SOLE |
| 02157Q109 | ANRO | Alto Neuroscience Inc | $44.2M | 1.50% | 2,485,000 | Common | SOLE |
| 03770N101 | APGE | Apogee Therapeutics Inc | $41.5M | 1.41% | 550,000 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals Inc | $41.3M | 1.40% | 1,650,000 | Common | SOLE |
| 05464T104 | AXSM | Axsome Therapeutics Inc | $38.4M | 1.30% | 210,000 | Common | SOLE |
| 04351P101 | ASNDUSD | Ascendis Pharma A/S | $37.3M | 1.27% | 175,000 | Common | SOLE |
| 75383L102 | RAPP | Rapport Therapeutics Inc | $33.7M | 1.14% | 1,110,000 | Common | SOLE |
| 83422E204 | SLDB | Solid Biosciences Inc | $32.8M | 1.12% | 5,815,000 | Common | SOLE |
| 15117B202 | CLDX | Celldex Therapeutics Inc | $31.6M | 1.08% | 1,165,000 | Common | SOLE |
| 80706P103 | SRRK | Scholar Rock Holding Corp | $30.8M | 1.05% | 700,000 | Common | SOLE |
| 483497103 | KALV | KalVista Pharmaceuticals Inc | $30.5M | 1.04% | 1,890,000 | Common | SOLE |
| 92337R101 | VERA | Vera Therapeutics Inc | $27.9M | 0.95% | 550,000 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc | $26.9M | 0.91% | 600,000 | Common | SOLE |
| 516544103 | LNTH | Lantheus Holdings Inc | $24.0M | 0.81% | 360,000 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines Inc | $23.5M | 0.80% | 295,000 | Common | SOLE |
| 98985Y108 | ZYME | Zymeworks Inc | $22.8M | 0.77% | 865,000 | Common | SOLE |
| 45258D105 | IMCR | Immunocore Holdings PLC | $20.3M | 0.69% | 585,000 | Common | SOLE |
| 91678A107 | UPB | Upstream Bio Inc | $19.5M | 0.66% | 720,000 | Common | SOLE |
| 08659B102 | BBNX | Beta Bionics Inc | $18.3M | 0.62% | 600,000 | Common | SOLE |
| G2545C104 | CBIO | Crescent Biopharma Inc | $17.8M | 0.60% | 1,500,000 | Common | SOLE |
| 09058V103 | BCRX | BioCryst Pharmaceuticals Inc | $17.6M | 0.60% | 2,250,000 | Common | SOLE |
| 70975L107 | PEN | Penumbra Inc | $15.5M | 0.53% | 50,000 | Common | SOLE |
| 374163103 | GERN | Geron Corp | $14.9M | 0.51% | 11,320,000 | Common | SOLE |
| 759916109 | RGEN | Repligen Corp | $13.6M | 0.46% | 83,000 | Common | SOLE |
| 98956P102 | ZBH | Zimmer Biomet Holdings Inc | $13.5M | 0.46% | 150,000 | Common | SOLE |
| 110122108 | BMY | Bristol-Myers Squibb Co | $13.5M | 0.46% | 250,000 | Common | SOLE |
| 61225M102 | GLUE | Monte Rosa Therapeutics Inc | $12.2M | 0.41% | 775,000 | Common | SOLE |
| 359616109 | FULC | Fulcrum Therapeutics Inc | $10.7M | 0.37% | 950,000 | Common | SOLE |
| 805111101 | SVRA | Savara Inc | $9.7M | 0.33% | 1,606,000 | Common | SOLE |
| 29286M105 | — | Engene Holdings Inc | $9.5M | 0.32% | 1,055,000 | Common | SOLE |
| 00847X104 | AGIO | Agios Pharmaceuticals Inc | $8.8M | 0.30% | 325,000 | Common | SOLE |
| 60255C885 | BRD1EUR | Definium Therapeutics Inc | $8.5M | 0.29% | 637,000 | Common | SOLE |
| 24823R105 | DNLI | Denali Therapeutics Inc | $7.7M | 0.26% | 465,000 | Common | SOLE |
| 62855J104 | MYGN | Myriad Genetics Inc | $7.5M | 0.26% | 1,223,000 | Common | SOLE |
| 878972108 | TECX | Tectonic Therapeutic Inc | $6.8M | 0.23% | 328,000 | Common | SOLE |
| G6674U108 | NVCR | Novocure Ltd | $6.8M | 0.23% | 525,000 | Common | SOLE |
| 56565P103 | MPLT | MapLight Therapeutics Inc | $6.8M | 0.23% | 385,000 | Common | SOLE |
| 375558103 | GILD | Gilead Sciences Inc | $6.1M | 0.21% | 50,000 | Common | SOLE |
| 92915B106 | VYGR | Voyager Therapeutics Inc | $5.8M | 0.20% | 1,475,000 | Common | SOLE |
| 23306J309 | DBVT | DBV Technologies SA | $5.8M | 0.20% | 300,000 | Common | SOLE |
| 604749101 | MIRM | Mirum Pharmaceuticals Inc | $5.2M | 0.18% | 66,000 | Common | SOLE |
| B6S7WD106 | NYXH | Nyxoah SA | $5.1M | 0.17% | 1,107,000 | Common | SOLE |
| 670703107 | NUVL | Nuvalent Inc | $4.6M | 0.16% | 46,000 | Common | SOLE |
| 52635N103 | LENZ | LENZ Therapeutics Inc | $4.4M | 0.15% | 275,000 | Common | SOLE |
| 76200L309 | RZLT | Rezolute Inc | $4.0M | 0.14% | 1,686,000 | Common | SOLE |
| 702712209 | PASG | Passage Bio Inc | $3.6M | 0.12% | 305,000 | Common | SOLE |
| 869367201 | STRO | Sutro Biopharma Inc | $2.8M | 0.10% | 243,000 | Common | SOLE |
| 86366E106 | GPCR | Structure Therapeutics Inc | $2.4M | 0.08% | 35,000 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics Inc | $2.3M | 0.08% | 120,000 | Common | SOLE |
| 09203E105 | BDTX | Black Diamond Therapeutics Inc | $2.1M | 0.07% | 870,000 | Common | SOLE |
| 68277Q105 | OKUR | OnKure Therapeutics Inc | $1.8M | 0.06% | 635,000 | Common | SOLE |
| 31189P102 | FATE | Fate Therapeutics Inc | $1.7M | 0.06% | 1,725,000 | Common | SOLE |
| 014442107 | ALEC | Alector Inc | $1.2M | 0.04% | 755,000 | Common | SOLE |
| 88032L605 | TENX | Tenax Therapeutics Inc | $651,421 | 0.02% | 53,439 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO Inc | $489,600 | 0.02% | 34,000 | Common | SOLE |
| 556099109 | MGNX | MacroGenics Inc | $450,800 | 0.02% | 280,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.